HCA Healthcare, Inc. (NYSE: HCA)

Sector: Healthcare Industry: Medical Care Facilities CIK: 0000860730
Market Cap 105.95 Bn
P/E 16.43
P/S 1.40
Div. Yield 0.01
ROIC (Qtr) -0.22
Total Debt (Qtr) 46.49 Bn
Revenue Growth (1y) (Qtr) 6.72
Add ratio to table...

About

Investment thesis

Bull case

  • HCA’s 2025 results demonstrate a robust revenue base with a 6.7% year‑over‑year increase, driven by a combination of network expansion and high occupancy rates that consistently hover above 72%. The company’s ability to maintain a 20%+ adjusted EBITDA margin amid rising costs indicates strong pricing power and effective cost management, which is a key lever for sustaining profitability as the healthcare environment evolves. Moreover, the strategic capital allocation plan—highlighted by $5–$5.5 billion in 2026 capital spending—focuses on high‑acuity inpatient facilities and outpatient surgical centers, positioning HCA to capture the anticipated shift toward outpatient care and less invasive procedures, a trend that is expected to outpace inpatient volumes.
  • The digital transformation agenda, particularly the AI‑driven revenue cycle and capacity‑management initiatives, has already yielded measurable improvements in days in accounts receivable and operational efficiency. By standardizing data across its 190 hospitals and 2,500 ambulatory sites, HCA is creating a scalable platform that can be leveraged for future predictive analytics and clinical decision support, potentially driving higher quality outcomes and lower readmission rates. The company’s recent recognition on Healthgrades’ top hospital lists reinforces its clinical excellence narrative, which can enhance payer negotiations and attract higher‑volume referral traffic, thereby supporting incremental revenue growth.
  • HCA’s shareholder return policy is aggressive yet disciplined: a $10 billion share‑repurchase program, a quarterly dividend increase from $0.72 to $0.78, and $2.6 billion in repurchases during 2025. This signals management confidence in the company’s cash generation capabilities, with operating cash flow projected at $12–$13 billion in 2026, comfortably covering debt service and supporting future capital deployments. The low debt‑to‑adjusted EBITDA leverage range further underpins the firm’s ability to maintain a healthy balance sheet while investing in growth and returning capital to shareholders.
  • The resiliency program, quantified at a $400 million EBITDA offset in 2026, addresses the projected $600–$900 million headwind from health insurance exchange reforms and the expiration of enhanced premium tax credits. By combining revenue integrity initiatives, cost efficiencies, and capacity management, the program is positioned to partially neutralize policy‑induced revenue erosion, preserving margin expansion. This proactive stance mitigates one of the most significant regulatory risks facing large health systems and can provide a competitive edge over peers less prepared for the exchange transition.
  • HCA’s outpatient expansion strategy is particularly compelling; the company added approximately 100 new outpatient facilities in 2025 and continues to pursue acquisitions that complement its geographic footprint. Outpatient surgery volumes, though flat in 2024, are projected to grow as patient preference shifts toward minimally invasive procedures and lower cost settings. With 39.7% of total revenues coming from outpatient sources—a figure already above the industry average—HCA is well positioned to capture the long‑term shift toward ambulatory care, reinforcing its revenue diversification and resilience against inpatient downturns.
Read more

Bear case

  • The 2026 guidance explicitly acknowledges a potential $600–$900 million adverse impact on adjusted EBITDA from health insurance exchange reforms, including the expiration of enhanced premium tax credits. This headwind represents a sizable contraction relative to the $4.0 billion in 2025 adjusted EBITDA and could erode operating margins if not fully offset by the resiliency program. The company’s sensitivity to exchange volume declines is further amplified by the projected 15–20% drop in exchange‑derived admissions, which will likely shift a significant portion of that volume into uninsured categories, creating higher uncompensated care costs.
  • Medicaid supplemental payment programs pose a second critical risk; management projects a $250–$450 million decline in net benefit in 2026 due to state‑level changes in Tennessee, a pause in Texas, and the timing of a retroactive Virginia payment. These programs currently provide a vital subsidy stream that offsets the cost of treating low‑income patients; any reduction directly squeezes margins and increases the burden of cost‑sharing and collections. The unpredictability of state‑level policy shifts adds a layer of regulatory risk that could manifest as sudden cash outflows or loss of revenue streams.
  • Physician cost pressures are highlighted by CFO Mike Hart, who cautioned that physician costs could rise “in the high single digits” in 2026 versus 2025. Given the industry’s ongoing labor shortage, wage inflation is already in motion, and HCA’s large, multi‑state footprint may amplify negotiation leverage for physicians. Rising provider costs, if not matched by pricing power or efficiency gains, will erode the adjusted EBITDA margin, counteracting the 80‑basis‑point improvement seen in 2025.
  • The company’s heavy reliance on capital spending—$5–$5.5 billion in 2026—introduces exposure to interest rate fluctuations and debt service costs. While current leverage remains low, a tightening of credit markets could increase borrowing costs or constrain refinancing, squeezing free cash flow. Moreover, capital expenditures in high‑cost acquisition or expansion projects carry execution risk; delays or cost overruns can compress short‑term profitability without delivering the anticipated revenue lift.
  • Outpatient surgical volume trends show a modest decline; outpatient surgeries dropped 0.5% YoY, and ASCs down 1.5% in Q4 2025. This indicates potential competitive pressure from free‑standing surgical centers or shifting patient preferences toward alternative care models. If HCA cannot reverse this downward trajectory, it risks losing market share in the high‑margin ambulatory segment, which is critical for balancing the lower margins inherent in inpatient services.
Read more

Consolidation Items Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Care Facilities
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 HCA HCA Healthcare, Inc. 105.95 Bn 16.43 1.40 46.49 Bn
2 THC Tenet Healthcare Corp 16.36 Bn 12.06 0.77 13.17 Bn
3 CHE Chemed Corp 14.32 Bn 20.68 5.66 -
4 ENSG Ensign Group, Inc 11.42 Bn 32.70 2.27 0.14 Bn
5 EHC Encompass Health Corp 11.28 Bn 17.36 1.90 2.49 Bn
6 DVA Davita Inc. 9.97 Bn 14.47 0.78 10.27 Bn
7 FMS Fresenius Medical Care AG 7.30 Bn 5.68 0.37 8.49 Bn
8 OPCH Option Care Health, Inc. 5.06 Bn 21.44 0.90 1.16 Bn